Mínimo 3 entidades de 3 países
The rapid rise of AMR presents a formidable threat to public health, challenging our ability to treat infections that were once easily managed with standard antimicrobials. As pathogens continually adapt and develop resistance to existing drugs, the efficacy of these treatments diminishes, leading to more severe and prolonged illnesses, increased healthcare costs and productivity losses, and higher mortality rates.
Ver en el portal de la ComisiónFuente:Portal Funding & Tenders (Comisión Europea), actualizado el 29 oct 2026